# US 2010/0137344 A1 · Induction of analgesia in neuropathic pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0137344 A1
- Document ID: US20100137344A1
- Status: Published application
- Kind: A1
- Application number: 12/375,627
- Filed: 2007-07-27
- Published: 2010-06-03
- Earliest claimed: 2006-07-29
- Assignees: The University Court of the University of Edinburgh
- Inventors: Susan Fleetwood-Walker; Rory Mitchell; Clare W.J. Proudfoot
- Web page: https://patentgrep.com/patent/US20100137344A1

## CPC

- A61K 36/534: Mentha (mint)
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to agents which are capable of inducing analgesia in chronic neuropathic pain, associated methods and uses thereof. In particular, the present invention provides compounds capable of activating the TRPM8 receptor for the treatment of chronic neuropathic pain.

## Claims

### Claim at position 1

1-44. (canceled)

### Claim 45

A method of treating chronic neuropathic pain, said method comprising the step of administering an effective amount of a transient receptor potential (TRP) M8 cation cannel activating agent to a patient suffering from or experiencing chronic neuropathic pain, wherein the TRPM8 cation channel activating agent is selected from the group consisting of:
(i) icilin (1-(2′-hydroxyphenyl)-4-(3″-nitrophenyl)-1,2,3,6-tetrahydropyrimidin-2-one);
(ii) menthol (1R,2S,5R-(5-methyl-2-[1-methylethyl]cyclohexanol);
(iii) WS-12 (2-isopropyl-5-methyl-cyclohexanecarboxylic acid (4-methoxyphenyl) amide); and
(iv) derivatives of any of (i)-(iv).

### Claim 46 (depends on 45)

The method of claim 45, wherein the chronic neuropathic pain results in one or more of hyperalgesia, allodynia and spontaneous pain.

### Claim 47 (depends on 45)

The method of claim 45, wherein icilin comprises a modification at the 2′ position to include a member selected from the group consisting of:
(i) C1-C4 alkyloxy;
(ii) NO2;
(iii) ═O; and
(iv) NH2.

### Claim 48 (depends on 45)

The method of claim 45, wherein the TRPM8 cation channel activating agent is icilin, methoxyicilin or a derivative thereof.

### Claim 49 (depends on 45)

The method of claim 45, wherein the TRPM8 cation channel activating agent is menthol, for example (−)-menthol.

### Claim 50 (depends on 45)

The method of claim 45, wherein the TRPM8 cation channel activating agent is the menthyl derivative compound (2-isopropyl-5-methyl-cyclohexanecarboxylic acid (4-methoxyphenyl)amide) (WS12).

### Claim 51 (depends on 45)

The method of claim 45, wherein the chronic neuropathic pain is selected from the following pain states:
(i) Trauma-induced neuropathic pain.
(ii) Demyelination-induced pain.
(iii) Inflammatory pain states.
(iii) Phantom-limb pain.
(iv) Neuropathic pain linked to cancer.
(v) Chemotherapy-induced neuropathy.
(vi) Back pain.
(v) Bone pain and cancer-induced bone pain.

### Claim 52 (depends on 51)

The method of claim 51, wherein the inflammatory pain state is associated with arthritis.

### Claim 53 (depends on 45)

The method of claim 45, wherein the medicament is administered at a peripheral site.

### Claim 54 (depends on 45)

The method of claim 45, wherein the medicament is administered topically, intrathecally, as an epidural or transdermally.

### Claim 55 (depends on 54)

The method of claim 54, wherein the transdermal administration is via a transdermal delivery device.

### Claim 56 (depends on 45)

The method of claim 45, wherein the medicament is administered with another compound or compounds.

### Claim 57

A pharmaceutical composition comprising a TRPM8 cation channel activating agent selected from the group consisting of:
(ii) icilin (1-(2′-hydroxyphenyl)-4-(3″-nitrophenyl)-1,2,3,6-tetrahydropyrimidin-2-one);
(iii) menthol (1R,2S,5R-(5-methyl-2-[1-methylethyl]cyclohexanol);
(iv) WS-12 (2-isopropyl-5-methyl-cyclohexanecarboxylic acid (4-methoxyphenyl) amide); and
(v) derivatives of any of (i)-(iv).
and a pharmaceutically acceptable carrier or excipient.

### Claim 58 (depends on 57)

The composition of claim 57 formulated for topical, intrathecal, epidural and/or transdermal administration/delivery.

### Claim 59

A method of detecting an agent potentially useful in a method of inducing analgesia in a patient suffering from or experiencing chronic neuropathic pain, said method comprising the step of;
(a) contacting a test agent or agents with a TRPM8 receptor; and
(b) detecting any activation of the TRPM8 receptor so as to identify an agent or agents which activates the TRPM8 receptor.

### Claim 60 (depends on 59)

The method of claim 59, wherein the TRPM8 receptor is:
a. expressed on the surface of a cell;
b. provided by a recombinant system; and/or
c. provided by a tissue sample or biopsy.

### Claim 61 (depends on 60)

The method of claim 60, wherein the cell, is derived from the human prostate carcinoma cell line

### Claim 62 (depends on 59)

The method of claim 59 comprising the further step of testing an agent found to activate the TRPM8 receptor for an analgesic effect.

### Claim 63 (depends on 59)

The method of claim 59, wherein the agent is tested on a subject know to be suffering from or experiencing chronic neuropathic pain

### Claim 64 (depends on 63)

The method of claim 63, wherein the test comprises the step of topically administering the agent to the skin of the subject

### Claim 65 (depends on 59)

The method of claim 59, wherein the agent or agents are tested on an animal model.

### Claim 66

A method of detecting agents which are capable of binding to the TRPM8 receptor, said method comprising the steps of;
(a) contacting a test agent or agents with a TRPM8 receptor; and
(b) detecting any binding which occurs between the test agent and the TRPM8 receptor.

### Claim 67 (depends on 66)

The method of claim 66, wherein binding is detected by means of a displacement of a known TRPM8 binding agent and/or a band shift assay.

### Claim 68 (depends on 66)

The method of claims 66, wherein the results are compared with those obtained from a control system wherein the TRPM8 receptor has not been contacted with the test agent or agents.

### Claim 69

A method of treating a patient suffering from or experiencing chronic neuropathic pain, said method comprising the step of administering an effective amount of an agent or compound which directly activates a Group II/III mGluR and an agent or compound which indirectly activates a group II/III mGluR, wherein the agent capable of directly activating a Group II/III mGluR is selected from the group consisting of:
(i) 2R,4R-APDC;
(ii) ACPT-III; and
(iii) AP-4;
and the agent capable of indirectly activating a Group II/III mGluR is selected from the group consisting of:
(iv) icilin (1-(2′-hydroxyphenyl)-4-(3″-nitrophenyl)-1,2,3,6-tetrahydropyrimidin-2-one);
(v) menthol 1R,2S,5R-(5-methyl-2-[1-methylethyl]cyclohexanol);
(vi) WS-12 (2-isopropyl-5-methyl-cyclohexanecarboxylic acid (4-methoxyphenyl) amide); and
(vii) derivatives of any of (iv)-(vi).

### Claim 70 (depends on 69)

The method of claim 69, wherein icilin comprises a modification at the 2′ position selected from the group consisting of:
(i) C1-C4 alkyloxy;
(ii) OH;
(iii) NO2;
(iv) ═O; and
(v) NH2.

### Claim 71 (depends on 69)

The method of claim 69, wherein agents capable of directly/indirectly inactivating Group II/III mGluRs is icilin, methoxyicilin or a variant, derivative or variant thereof.

### Claim 72 (depends on 69)

The method of claim 69, wherein the agent capable of indirectly activating the Group II/III mGluRs is menthol, for example (−)-menthol.

### Claim 73 (depends on 69)

The method of claim 69, wherein the agent capable of indirectly activating the Group II/III mGluRs is the menthyl derivative compound (2-isopropyl-5-methyl-cyclohexanecarboxylic acid (4-methoxyphenyl)amide) (WS12).
